期刊： JOURNAL OF HEALTH POLITICS POLICY AND LAW, 2022; 47 (3)
Context: American Indian elders have a lower life expectancy than other aging populations in the United States because of inequities in health and in ......
期刊： JOURNAL OF HEALTH POLITICS POLICY AND LAW, 2022; 47 (1)
The No Surprises Act, passed by Congress at the end of 2020, offers significant protections to most Americans with private health insurance. Insured A......
期刊： JOURNAL OF HEALTH POLITICS POLICY AND LAW, 2022; 47 (1)
Context: Despite numerous examples of health policy transfer in Western health systems, the nature of such inspired reforms has received little detail......
期刊： JOURNAL OF HEALTH POLITICS POLICY AND LAW, 2022; 47 (4)
Context: On March 19, 2020, President Donald Trump endorsed using hydroxychloroquine for COVID-19 treatment despite inconclusive evidence of the drug'......
期刊： JOURNAL OF HEALTH POLITICS POLICY AND LAW, 2022; 47 (1)
The No Surprises Act, passed by Congress at the end of 2020, offers significant protections to most Americans with private health insurance. Insured A......
期刊： JOURNAL OF HEALTH POLITICS POLICY AND LAW, 2022; 47 (6)
Consumer cost sharing is widely employed by payers in the United States in an effort to control spending. Most cost-sharing strategies set patient con......
期刊： JOURNAL OF HEALTH POLITICS POLICY AND LAW, 2022; 47 (6)
More than 40 years have passed since the enactment of the Patent and Trademark Amendment (Bayh-Dole) Act, which authorized institutions to patent inve......
期刊： JOURNAL OF HEALTH POLITICS POLICY AND LAW, 2022; 47 (5)
Context: Dramatic increases in pharmaceutical merger and acquisition (M&A) activity since 2010 suggest we are in the midst of a third wave of indu......
期刊： JOURNAL OF HEALTH POLITICS POLICY AND LAW, 2022; 47 (6)
Some of the news about insulin is shocking. In the United States, people have died because they were rationing a life-saving medication discovered in ......
期刊： JOURNAL OF HEALTH POLITICS POLICY AND LAW, 2022; 47 (6)
International reference prices (IRP), also called external reference prices, are widely used across developed nations. IRP uses the prices paid in oth......
期刊： JOURNAL OF HEALTH POLITICS POLICY AND LAW, 2022; 47 (6)
Context: When nonretail pharmacy sales exceed 70% of sales, manufacturers of infused, injected, implanted, inhaled, or instilled (5i) drugs are requir......
期刊： JOURNAL OF HEALTH POLITICS POLICY AND LAW, 2022; 47 (6)
Context: To what extent does pharmaceutical revenue growth depend on new medicines versus increasing prices for existing medicines? Moreover, does usi......
期刊： JOURNAL OF HEALTH POLITICS POLICY AND LAW, 2022; 47 (6)
Context: New drug approvals in the United States must be supported by substantial evidence from adequate and well-controlled trials. The Food and Drug......
